PBYINasdaqPharmaceutical PreparationsFiscal year ends December 31
PUMA BIOTECHNOLOGY, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$10.21+0.38 (+3.87%)
Close on Oct 19, 2026
- Market cap
- $537.01M
- P/E (TTM)
- 19.6
- Dividend yield
- –
PUMA BIOTECHNOLOGY, INC. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Product [Member] | $204.07M | $195.19M | $203.11M | $200.02M | $189.06M | $196.73M | $211.62M | $200.49M | $26.19M | 89.4% | +4.6% |
| Royalty [Member] | $24.30M | $35.28M | $32.53M | $28.01M | $12.34M | $5.68M | $391.00K | – | – | 10.6% | -31.1% |
| License [Member] | – | – | $0 | $0 | $51.75M | $22.70M | $60.25M | $50.50M | $1.50M | – | – |
| NERLYNX [Member] | – | – | – | $250.00M | – | – | – | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Puma Biotechnology's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.